BACKGROUND: Twenty-five percent of new anti-factor VIII (FVIII) antibodies (inhibitors) that complicate hemophilia A occur in those with mild and moderate disease. Although intensive FVIII treatment has long been considered a risk factor for inhibitor development in those with non-severe disease, its strength of association and the influence of other factors have remained undefined. OBJECTIVE: To evaluate risk factors for inhibitor development in patients with non-severe hemophilia A. METHODS: Information on clinical and demographic variables and FVIII genotype was collected on 36 subjects with mild or moderate hemophilia A and an inhibitor and 62 controls also with mild or moderate hemophilia A but without an inhibitor. RESULTS: Treatment with FVIII for six or more consecutive days during the prior year was more strongly associated with inhibitor development in those ≥30years of age compared with those <30years of age [adjusted odds ratio (OR) 12.62; 95% confidence interval (CI), 2.76-57.81 vs. OR 2.54; 95% CI, 0.61-10.68]. Having previously received <50days of FVIII was also not statistically associated with inhibitor development on univariate or multivariate analysis. CONCLUSIONS: These findings suggest that inhibitor development in mild and moderate hemophilia A varies with age, but does not vary significantly with lifetime FVIII exposure days: two features distinct from severe hemophilia A.
BACKGROUND: Twenty-five percent of new anti-factor VIII (FVIII) antibodies (inhibitors) that complicate hemophilia A occur in those with mild and moderate disease. Although intensive FVIII treatment has long been considered a risk factor for inhibitor development in those with non-severe disease, its strength of association and the influence of other factors have remained undefined. OBJECTIVE: To evaluate risk factors for inhibitor development in patients with non-severe hemophilia A. METHODS: Information on clinical and demographic variables and FVIII genotype was collected on 36 subjects with mild or moderate hemophilia A and an inhibitor and 62 controls also with mild or moderate hemophilia A but without an inhibitor. RESULTS: Treatment with FVIII for six or more consecutive days during the prior year was more strongly associated with inhibitor development in those ≥30years of age compared with those <30years of age [adjusted odds ratio (OR) 12.62; 95% confidence interval (CI), 2.76-57.81 vs. OR 2.54; 95% CI, 0.61-10.68]. Having previously received <50days of FVIII was also not statistically associated with inhibitor development on univariate or multivariate analysis. CONCLUSIONS: These findings suggest that inhibitor development in mild and moderate hemophilia A varies with age, but does not vary significantly with lifetime FVIII exposure days: two features distinct from severe hemophilia A.
Authors: Wendy S Bril; Ellen A M Turenhout; Paul H P Kaijen; Edward N van den Brink; Maria M W Koopman; Marjolein Peters; Jan Voorberg Journal: Br J Haematol Date: 2002-11 Impact factor: 6.998
Authors: C R Hay; C A Ludlam; B T Colvin; F G Hill; F E Preston; N Wasseem; R Bagnall; I R Peake; E Berntorp; E P Mauser Bunschoten; K Fijnvandraat; C K Kasper; G White; E Santagostino Journal: Thromb Haemost Date: 1998-04 Impact factor: 5.249
Authors: A Sharathkumar; D Lillicrap; V S Blanchette; M Kern; J Leggo; A M Stain; L Brooker; M D Carcao Journal: J Thromb Haemost Date: 2003-06 Impact factor: 5.824
Authors: Johannes Oldenburg; Jörg Schröder; Hans Hermann Brackmann; Clemens Müller-Reible; Rainer Schwaab; Edward Tuddenham Journal: Semin Hematol Date: 2004-01 Impact factor: 3.851
Authors: J Michael Soucie; Christy Cianfrini; Robert L Janco; Roshni Kulkarni; Julie Hambleton; Bruce Evatt; Angela Forsyth; Sue Geraghty; Keith Hoots; Tom Abshire; Randall Curtis; Ann Forsberg; Heather Huszti; Margaret Wagner; Gilbert C White Journal: Blood Date: 2003-11-13 Impact factor: 22.113
Authors: S C Darby; D M Keeling; R J D Spooner; S Wan Kan; P L F Giangrande; P W Collins; F G H Hill; C R M Hay Journal: J Thromb Haemost Date: 2004-07 Impact factor: 5.824
Authors: Devi Gunasekera; Ruth A Ettinger; Shelley Nakaya Fletcher; Eddie A James; Maochang Liu; John C Barrett; Janice Withycombe; Dana C Matthews; Melinda S Epstein; Richard J Hughes; Kathleen P Pratt Journal: Blood Date: 2015-01-23 Impact factor: 22.113
Authors: Christine L Kempton; Geoff Allen; Jeffrey Hord; Rebecca Kruse-Jarres; Rajiv K Pruthi; Christopher Walsh; Guy Young; J Michael Soucie Journal: Am J Hematol Date: 2012-06-26 Impact factor: 10.047
Authors: Ryan J Summers; Shannon L Meeks; John F Healey; Harrison C Brown; Ernest T Parker; Christine L Kempton; Christopher B Doering; Pete Lollar Journal: Blood Date: 2011-01-07 Impact factor: 22.113